Study S003200

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes

ClinicalTrials.gov record

Registration

Registration: NCT07458269
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 264
Start: 2026-03-04
Primary completion: 2027-05
Lead sponsor: Kailera
Conditions: Obesity
Interventions: DRUG:Ribupatide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Percent Change From Baseline in Body Weight at Week 48 [Baseline, Week 48]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.